Firm will manufacture material for use in Phase II study.
Cobra Biomanufacturing will produce material for use in Advaxis’ Phase II trial of its cervical cancer vaccine, Lovaxin C. Cobra has been supporting the Advaxis Lovaxin C clinical program since 2003, according to David Thatcher, CEO of Cobra.
“We look forward to continuing our relationship with Cobra as we move forward with the development of live Listeria vaccines for the treatment of cancer,” says John Rothman, vp, clinical development. “Our initial clinical work demonstrated the real-world utility of our concepts, and Cobra’s ability to execute their production as potential cancer immunotherapeutic agents.”
